The National Heart, Lung, and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The grant, awarded on March 6, 2025, will fund research to determine the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The study aims to reveal key roles for these methyltransferases and the post-transcriptomic profile of cardiac mRNAs during early cardiac myogenesis, in order to uncover novel mechanisms underlying the development of fetal DCM and inform potential therapeutic strategies. The project will leverage mouse genetics, biochemistry, molecular biology, RNA biology, and histology techniques.
Generated 3/25/25, 4:59 AM